Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Stock analysts at Oppenheimer raised their Q1 2018 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Wednesday. Oppenheimer analyst L. Cann now expects that the biopharmaceutical company will post earnings per share of ($1.57) for the quarter, up from their previous forecast of ($2.06). Oppenheimer currently has a “Market Perform” rating on the stock. Oppenheimer also issued estimates for Agios Pharmaceuticals’ Q2 2018 earnings at ($1.57) EPS, Q3 2018 earnings at ($1.89) EPS, FY2018 earnings at ($5.60) EPS, FY2019 earnings at ($0.01) EPS, FY2020 earnings at $4.79 EPS and FY2021 earnings at $6.52 EPS.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The firm had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $12.65 million. During the same period in the previous year, the business earned ($1.34) earnings per share. The business’s revenue for the quarter was down 56.7% on a year-over-year basis.
Several other equities analysts also recently weighed in on AGIO. Credit Suisse Group raised their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. SunTrust Banks set a $80.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, BidaskClub downgraded Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 16th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $85.50.
Agios Pharmaceuticals (AGIO) opened at $77.70 on Monday. Agios Pharmaceuticals has a one year low of $45.11 and a one year high of $82.96.
In other news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $76.04, for a total transaction of $228,120.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $61.55, for a total value of $369,300.00. Following the sale, the chief executive officer now owns 6,000 shares in the company, valued at approximately $369,300. The disclosure for this sale can be found here. Insiders have sold 183,114 shares of company stock valued at $13,866,025 in the last three months. 5.43% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of AGIO. Alkeon Capital Management LLC acquired a new position in Agios Pharmaceuticals in the third quarter valued at $30,489,000. UBS Asset Management Americas Inc. boosted its holdings in Agios Pharmaceuticals by 965.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock valued at $19,740,000 after acquiring an additional 312,878 shares during the last quarter. First Trust Advisors LP boosted its holdings in Agios Pharmaceuticals by 26.3% in the fourth quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock valued at $46,516,000 after acquiring an additional 169,331 shares during the last quarter. OppenheimerFunds Inc. boosted its holdings in Agios Pharmaceuticals by 679.7% in the fourth quarter. OppenheimerFunds Inc. now owns 142,283 shares of the biopharmaceutical company’s stock valued at $8,134,000 after acquiring an additional 124,035 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its holdings in Agios Pharmaceuticals by 81.5% in the second quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock valued at $13,733,000 after acquiring an additional 119,836 shares during the last quarter. Hedge funds and other institutional investors own 84.04% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/02/20/agios-pharmaceuticals-inc-expected-to-earn-q1-2018-earnings-of-1-57-per-share-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.